Baseline patient characteristics
| Baseline characteristics . | O-DHAP (n = 26) . | O-ICE (n = 35) . | Total (n = 61) . |
|---|---|---|---|
| Age, y | |||
| Median | 54 | 52 | 53 |
| Range | 20–66 | 27–79 | 20–79 |
| Sex, n (%) | |||
| Male | 15 (58) | 20 (57) | 35 (57) |
| Female | 11 (42) | 15 (43) | 26 (43) |
| Histology, n (%) | |||
| DLBCL | 21 (81) | 26 (74) | 47 (77) |
| GCB subtype | 8 (31) | 14 (40) | 22 (36) |
| Non-GCB subtype | 7 (27) | 7 (20) | 14 (23) |
| Unknown subtype | 6 (23) | 5 (14) | 11 (18) |
| Grade 3B FL | 0 | 2 (6) | 2 (3) |
| Transformed FL | 5 (19) | 7 (20) | 12 (20) |
| saaIPI, n (%) | |||
| 0 | 5 (19) | 7 (20) | 12 (20) |
| 1 | 8 (31) | 12 (34) | 20 (33) |
| 2 | 11 (42) | 14 (40) | 25 (41) |
| 3 | 2 (8) | 2 (6) | 4 (7) |
| Ann Arbor stage, n (%) | |||
| I–II | 9 (35) | 12 (34) | 21 (34) |
| III–IV | 17 (65) | 23 (66) | 40 (66) |
| Baseline ECOG PS, n (%) | |||
| 0 | 17 (65) | 12 (34) | 29 (48) |
| 1 | 7 (27) | 20 (57) | 27 (44) |
| 2 | 2 (8) | 3 (9) | 5 (8) |
| LDH, n (%) | |||
| Elevated | 16 (62) | 20 (57) | 36 (59) |
| Normal | 9 (34) | 15 (43) | 24 (39) |
| Unknown | 1 (4) | 0 | 1 (2) |
| Best response to first-line, n (%) | |||
| CR >12 mo | 4 (15) | 8 (23) | 12 (20) |
| CR ≤12 mo | 9 (35) | 9 (26) | 18 (30) |
| Primary refractory | 13 (50) | 16 (46) | 29 (48) |
| PR | 6 (23) | 9 (26) | 15 (25) |
| SD | 2 (8) | 2 (6) | 4 (7) |
| PD | 5 (19) | 5 (14) | 10 (16) |
| Unknown best response, PFS less than or equal to 12 mo | 0 | 2 (6) | 2 (3) |
| Baseline characteristics . | O-DHAP (n = 26) . | O-ICE (n = 35) . | Total (n = 61) . |
|---|---|---|---|
| Age, y | |||
| Median | 54 | 52 | 53 |
| Range | 20–66 | 27–79 | 20–79 |
| Sex, n (%) | |||
| Male | 15 (58) | 20 (57) | 35 (57) |
| Female | 11 (42) | 15 (43) | 26 (43) |
| Histology, n (%) | |||
| DLBCL | 21 (81) | 26 (74) | 47 (77) |
| GCB subtype | 8 (31) | 14 (40) | 22 (36) |
| Non-GCB subtype | 7 (27) | 7 (20) | 14 (23) |
| Unknown subtype | 6 (23) | 5 (14) | 11 (18) |
| Grade 3B FL | 0 | 2 (6) | 2 (3) |
| Transformed FL | 5 (19) | 7 (20) | 12 (20) |
| saaIPI, n (%) | |||
| 0 | 5 (19) | 7 (20) | 12 (20) |
| 1 | 8 (31) | 12 (34) | 20 (33) |
| 2 | 11 (42) | 14 (40) | 25 (41) |
| 3 | 2 (8) | 2 (6) | 4 (7) |
| Ann Arbor stage, n (%) | |||
| I–II | 9 (35) | 12 (34) | 21 (34) |
| III–IV | 17 (65) | 23 (66) | 40 (66) |
| Baseline ECOG PS, n (%) | |||
| 0 | 17 (65) | 12 (34) | 29 (48) |
| 1 | 7 (27) | 20 (57) | 27 (44) |
| 2 | 2 (8) | 3 (9) | 5 (8) |
| LDH, n (%) | |||
| Elevated | 16 (62) | 20 (57) | 36 (59) |
| Normal | 9 (34) | 15 (43) | 24 (39) |
| Unknown | 1 (4) | 0 | 1 (2) |
| Best response to first-line, n (%) | |||
| CR >12 mo | 4 (15) | 8 (23) | 12 (20) |
| CR ≤12 mo | 9 (35) | 9 (26) | 18 (30) |
| Primary refractory | 13 (50) | 16 (46) | 29 (48) |
| PR | 6 (23) | 9 (26) | 15 (25) |
| SD | 2 (8) | 2 (6) | 4 (7) |
| PD | 5 (19) | 5 (14) | 10 (16) |
| Unknown best response, PFS less than or equal to 12 mo | 0 | 2 (6) | 2 (3) |
ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; GCB, germinal center B cell; LDH, lactate dehydrogenase; O, ofatumumab; PD, progressive disease; PR, partial response; PS, performance status; saaIPI, second-line age-adjusted international prognostic index.